Why does my independent result sit 0.6% below the supplier certificate?

I have the report as a PDF with the chromatogram on page two, so I can quote specifics.

Something has gone wrong and I would like to know how badly before I decide what to do.

Nothing else in the setup changed, which is what makes this puzzling.

What would you check first, and what would you conclude from each outcome?

0.6 of a percentage point is inside the range two laboratories produce from the same vial, so the first hypothesis is method, not material. Gradient slope, detection wavelength, integration convention and the reporting threshold each move a purity figure by a few tenths, and they move it in a consistent direction: the method that resolves more impurities reports the lower number. A 0.6 point gap therefore tells you almost nothing on its own. It becomes evidence when it repeats — same direction, same magnitude, across three lots — because method differences are constant and material differences are not. Get the column, the gradient and the wavelength from both parties, and if either declines to supply them you have learned something more useful than 0.6 per cent.

Specifically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The part that matters: mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 31 May 2026 by sinead_gaffney — added the placebo-arm figures

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

The underlying point is that integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you are ranking vendors, specify a method and have all samples tested at the same place.

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

Compare purity within a single laboratory on the same method, never across laboratories.

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Specifically, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.